logo
Delcath Systems Issues Full Year 2025 Guidance

Delcath Systems Issues Full Year 2025 Guidance

Business Wire22-05-2025

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) ('Delcath' or the 'Company'), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced full year 2025 financial guidance and its intention to enter into a Medicaid National Drug Rebate Agreement (NDRA) to expand patient access.
2025 Full Year Financial Guidance
The Company's financial outlook for fiscal year 2025 is as follows:
Total CHEMOSAT and HEPZATO KIT revenue of $94 to $98 million, an increase of more than 150% over 2024
Gross margins between 83% to 85%
Positive adjusted EBITDA and cashflow in each quarter of 2025
National Medicaid Drug Rebate Agreement
Delcath will participate in the Medicaid Drug Rebate Program, which entails providing Medicaid rebates and 340B discounts to eligible entities. The Company has initiated the process of entering into the NDRA with the Centers for Medicare and Medicaid Services and expects it to take effect at the beginning of the third quarter of 2025.
'Our decision to enter into the NDRA simplifies Medicaid access and enables eligible hospitals to access 340B drug pricing. We believe this will expand treatment availability and accelerate adoption of HEPZATO in the United States,' said Gerard Michel, Chief Executive Officer of Delcath. 'Based on current center activation rates and rising utilization, we expect total HEPZATO treatment volume in 2025 to increase at least 200% versus 2024.'
About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT ® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.
In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT.
In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.
Safe Harbor / Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This press release contains forward-looking statements, including the Company's 2025 financial outlook, which are subject to certain risks and uncertainties, that can cause actual results to differ materially from those described. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the Company's ability to successfully enter into the NDRA and its potential impact on the Company's business and operation; the Company's commercialization plans and its ability to successfully commercialize the HEPZATO KIT; the Company's successful management of the HEPZATO KIT supply chain, including securing adequate supply of critical components necessary to manufacture and assemble the HEPZATO KIT; successful FDA inspections of the facilities of the Company and those of its third-party suppliers/manufacturers; the Company's successful implementation and management of the HEPZATO KIT Risk Evaluation and Mitigation Strategy; the potential benefits of the HEPZATO KIT as a treatment for patients with primary and metastatic disease in the liver; the Company's ability to obtain reimbursement for the HEPZATO KIT; and the Company's ability to successfully enter into any necessary purchase and sale agreements with users of the HEPZATO KIT. For additional information about these factors, and others that may impact the Company, please see the Company's filings with the Securities and Exchange Commission, including those on Forms 10-K, 10-Q, and 8-K. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, you should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Eaton and AMP IT Collaborate to Offer EV Charging-as-a-Service Integrated With Solar and Energy Storage to Building Owners in Switzerland
Eaton and AMP IT Collaborate to Offer EV Charging-as-a-Service Integrated With Solar and Energy Storage to Building Owners in Switzerland

Business Wire

time43 minutes ago

  • Business Wire

Eaton and AMP IT Collaborate to Offer EV Charging-as-a-Service Integrated With Solar and Energy Storage to Building Owners in Switzerland

GENEVA--(BUSINESS WIRE)--Eaton, a global leader in intelligent power management, and AMP IT SA, a company focused on financing, installing and operating electric vehicle charging systems, are collaborating on a new project to help building owners optimize the efficiency and system performance of electric vehicle charging infrastructure (EVCI) without the complexity of EVCI ownership. The project, which is targeted at scaling EV charging infrastructure in multi-residential , office, industrial and logistics buildings, is supported by the Swiss Federal Office of Energy after recently winning an award in its RechargeAuPoint program that promotes innovative projects in the field of charging infrastructure. In the context of this business model, Eaton's Buildings as a Grid approach combined with AMP IT's smart charging solutions makes it possible to manage the renewable and conventional energy requirements of a building without owning or maintaining related assets such as EV charging infrastructure, energy storage and solar panels. Eaton and AMP IT plan to roll out similar business models in other EMEA countries in the future. Leveraging the Buildings as a Grid approach to energy management, AMP IT has coordinated an impressive ecosystem of project partners. As well as Eaton, the partners include publicly traded real estate investment funds, experienced service operators, leading energy, procurement and construction (EPC) companies, local utility companies and academic partners interested in this transformative approach to EV charging by leveraging buildings as integral components of microgrids. 'Decentralized energy production and management is essential to meet growing global energy demands and this project shows how collaboration and technology developments such as our Buildings as a Grid approach will make the energy transition sustainable and profitable for everyone involved,' said Andreea Laplace, director, sustainability and energy transition offerings at Eaton. 'We trust that this program will bring significant contributions to e-mobility with smarter EV charging solutions making better use of locally produced renewable energies, enhanced energy self-consumption schemes, and cost-effective battery storage solutions, in various use cases,' said Ilya Tyuvildin, AMP IT co-founder. About AMP IT: AMP IT is a Swiss company that designs, finances, and installs smart electric vehicle (EV) charging solutions for homes, businesses, and multi-tenant buildings. Combining cutting-edge hardware with proprietary AI-driven software, AMP IT enables seamless and optimized charging experiences that increase self-consumption of solar energy, reduce grid stress, and lower electricity costs. By integrating solar production, battery storage, and flexible charging, AMP IT transforms EVs into active components of a more sustainable, resilient, and efficient energy ecosystem. About Eaton: Eaton is an intelligent power management company dedicated to protecting the environment and improving the quality of life for people everywhere. We make products for the data center, utility, industrial, commercial, machine building, residential, aerospace and mobility markets. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we're helping to solve the world's most urgent power management challenges and building a more sustainable society for people today and generations to come. Founded in 1911, Eaton has continuously evolved to meet the changing and expanding needs of our stakeholders. With revenues of nearly $25 billion in 2024, the company serves customers in more than 160 countries. For more information, visit Follow us on LinkedIn.

Workplace Injuries Are Reduced with Employee Appreciation
Workplace Injuries Are Reduced with Employee Appreciation

Business Wire

timean hour ago

  • Business Wire

Workplace Injuries Are Reduced with Employee Appreciation

LOUGHTON, England--(BUSINESS WIRE)--Latest research reveals that frequently recognising employees for their efforts and achievements can decrease the likelihood of workplace injuries among French workers by up to 50%. This is a key finding from O.C. Tanner's 2025 Global Culture Report which gathered data and insights from 38,075 workers from 27 countries including 1,208 from France. The report highlights how feeling unappreciated worsens mental health and this then increases the likelihood of workplace accidents. Robert Ordever, European MD of O.C. Tanner explains: 'There's a clear link between deteriorating mental health and greater instances of workplace injuries, with mental illness often leading to decreased concentration, reduced cognitive function, and impaired decision-making abilities. Workers struggling with their mental health have their condition worsened when they feel unappreciated by their managers and colleagues.' The Report highlights how regularly recognising employees for their efforts and achievements, not only improves workers' wellbeing, but noticeably reduces the odds of them reporting a workplace accident. Employees suffering from burnout are 50% less likely to have a workplace accident when their organisation has a formal recognition programme in place. For those workers with probable depression, their odds of reporting a workplace accident are 11% when their organisation is WITHOUT a recognition programme. For workers with probable depression but WITH a recognition programme in place, their odds of reporting a workplace accident are reduced to just 8%. Ordever says, 'Implementing a recognition programme that allows all employees to regularly express gratitude to colleagues, not only reduces the likelihood of burnout, anxiety, and depression, but also cuts the number of workplace injuries. But it's important to note that having a recognition programme is not enough in itself. The organisation must champion the giving of appreciation on a daily basis, and encourage recognition that's sincere, tailored to the individual and meaningful. When the importance of recognition is understood and prioiritised, organisations can enjoy truly impactful business outcomes.' About 2025 Global Culture Report The O.C. Tanner Institute uses multiple research methods to support the Global Culture Report, including interviews, focus groups, cross-sectional surveys, and a longitudinal survey. Qualitative findings came from 27 focus groups among employees, leaders, and HR practitioners of larger organisations. About O.C. Tanner O.C. Tanner is the global leader in personalised employee recognition solutions that improve workplace cultures so people feel appreciated, do their best work, and stay. Its Culture Cloud is a suite of apps and solutions, including recognition, service awards, wellbeing, leadership, and celebrations that help people thrive at work. O.C. Tanner provides these and other services for thousands of the most respected companies in the world. For more information visit

EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (EBR) Receives a Buy from Bell Potter
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (EBR) Receives a Buy from Bell Potter

Business Insider

timean hour ago

  • Business Insider

EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (EBR) Receives a Buy from Bell Potter

In a report released today, Martyn Jacobs from Bell Potter maintained a Buy rating on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (EBR – Research Report), with a price target of A$2.25. The company's shares closed last Friday at A$1.17. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Jacobs covers the Healthcare sector, focusing on stocks such as EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh, Trajan Group Holdings Ltd, and Medical Developments International Limited. According to TipRanks, Jacobs has an average return of -21.1% and a 13.58% success rate on recommended stocks. Currently, the analyst consensus on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh is a Strong Buy with an average price target of A$2.80, implying a 140.34% upside from current levels. In a report released on May 29, Wilsons also maintained a Buy rating on the stock with a A$3.00 price target.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store